Search Results - "DUBERTRET, L."

Pioneers in Dermatology and Venereology: an interview with Prof. Louis M.M. Dubertret by Dubertret, L.M.M.

Get full text

Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION) by Saurat, J.-H., Stingl, G., Dubertret, L., Papp, K., Langley, R.G., Ortonne, J.-P., Unnebrink, K., Kaul, M., Camez, A.

“…Summary Background  Biologic therapies such as adalimumab, a tumour necrosis factor antagonist, are safe and effective in the treatment of moderate to severe…”
Get full text

European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey by Dubertret, L., Mrowietz, U., Ranki, A., Van De Kerkhof, P.C.M., Chimenti, S., Lotti, T., Schäfer, G.

“…Summary Background  EUROPSO (European Federation of Psoriasis Patient Associations) undertook a Europe‐wide survey examining quality of life and patients’…”
Get full text

European S3-Guidelines on the systemic treatment of psoriasis vulgaris by Pathirana, D, Ormerod, AD, Saiag, P, Smith, C, Spuls, PI, Nast, A, Barker, J, Bos, JD, Burmester, G-R, Chimenti, S, Dubertret, L, Eberlein, B, Erdmann, R, Ferguson, J, Girolomoni, G, Gisondi, P, Giunta, A, Griffiths, C, Hönigsmann, H, Hussain, M, Jobling, R, Karvonen, S-L, Kemeny, L, Kopp, I, Leonardi, C, Maccarone, M, Menter, A, Mrowietz, U, Naldi, L, Nijsten, T, Ortonne, J-P, Orzechowski, H-D, Rantanen, T, Reich, K, Reytan, N, Richards, H, Thio, HB, Van De Kerkhof, P, Rzany, B

“…Of the 131 studies on monotherapy or combination therapy assessed, 56 studies on the different forms of phototherapy fulfilled the criteria for inclusion in…”
Get full text

Acitrétine by Dubertret, L.

Get full text

Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study by Viguier, M., Pagès, C., Aubin, F., Delaporte, E., Descamps, V., Lok, C., Beylot-Barry, M., Séneschal, J., Dubertret, L., Morand, J.-J., Dréno, B., Bachelez, H.

“…Summary Background  Even though efficacy of biologics has been extensively studied in psoriasis vulgaris, studies in erythrodermic psoriasis, the most severe…”
Get full text

CLinical experience acquired with the efalizumab (Raptiva®) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial by Dubertret, L., Sterry, W., Bos, J.D., Chimenti, S., Shumack, S., Larsen, C.G., Shear, N.H., Papp, K.A.

“…Summary Background  Efalizumab (anti‐CD11a), a humanized monoclonal antibody, blocks multiple T‐cell‐dependent functions implicated in the pathogenesis of…”
Get full text

Ciclosporin in psoriasis clinical practice: an international consensus statement by Griffiths, C.E.M., Dubertret, L., Ellis, C.N., Finlay, A.Y., Finzi, A.F., Ho, V.C., Johnston, A., Katsambas, A., Lison, A-E., Naeyaert, J.M., Nakagawa, H., Paul, C., Vanaclocha, F.

“…Summary The main recommendations for the use of ciclosporin in the management of psoriasis are: (i) intermittent short courses (average of 12 weeks duration)…”
Get full text

Gemcitabine treatment in cutaneous T-cell lymphoma: a multicentre study of 23 cases by Jidar, K., Ingen-Housz-Oro, S., Beylot-Barry, M., Paul, C., Chaoui, D., Sigal-Grinberg, M., Morel, P., Dubertret, L., Bachelez, H.

“…Summary Background  Primary cutaneous T‐cell lymphomas (CTCLs) are malignancies characterized by a clonal T‐cell infiltrate involving the skin. CTCLs often…”
Get full text

A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity by Poulalhon, N., Begon, E., Lebbé, C., Lioté, F., Lahfa, M., Bengoufa, D., Morel, P., Dubertret, L., Bachelez, H.

“…Summary Background  Infliximab, an antitumour necrosis factor‐α chimeric monoclonal antibody, is effective for the treatment of severe psoriasis. While the…”
Get full text

Acitretin by Dubertret, L

Get full text

Superiority of tacrolimus 0.1% ointment compared with fluticasone 0.005% in adults with moderate to severe atopic dermatitis of the face: results from a randomized, double-blind trial by Doss, N, Reitamo, S, Dubertret, L, Fekete, G L, Kamoun, M-R, Lahfa, M, Ortonne, J-P

“…No specific data are available on tacrolimus ointment as a second-line treatment in adults with facial eczema. To compare tacrolimus 0.1% and fluticasone…”
Get full text

Patient-based medicine by Dubertret, L

“…Every day, we have to solve two questions: The first question is how to evaluate the severity of diseases affecting mainly the quality of life (psoriasis,…”
Get full text

A randomized controlled evaluator-blinded trial of intravenous immunoglobulin in adults with severe atopic dermatitis by Paul, C., Lahfa, M., Bachelez, H., Chevret, S., Dubertret, L.

“…Summary Background There is a need for alternative therapy in severe adult atopic dermatitis (AD). Intravenous immunoglobulin (IVIG) treatment has been shown…”
Get full text

Inactivation of the CDKN2A and the p53 tumour suppressor genes in external genital carcinomas and their precursors by Soufir, N., Queille, S., Liboutet, M., Thibaudeau, O., Bachelier, F., Delestaing, G., Balloy, B.C., Breuer, J., Janin, A., Dubertret, L., Vilmer, C., Basset-Seguin, N.

“…Summary Background  p53 has been extensively studied in external genital carcinoma (EGC), and is frequently inactivated, but little is known about the role of…”
Get full text

Cosmetic dermatology and skin care by Kerscher, M, Williams, St, Dubertret, L

Get full text

Efficacy of tacrolimus 0.03% ointment as second-line treatment for children with moderate-to-severe atopic dermatitis: evidence from a randomized, double-blind non-inferiority trial vs. fluticasone 0.005% ointment by Doss, N., Kamoun, M.-R., Dubertret, L., Cambazard, F., Remitz, A., Lahfa, M., De Prost, Y.

“…Doss N, Kamoun M‐R, Dubertret L, Cambazard F, Remitz A, Lahfa M, de Prost Y. Efficacy of tacrolimus 0.03% ointment as second‐line treatment for children with…”
Get full text

Vitamin and trace metal levels in recessive dystrophic epidermolysis bullosa by Ingen-Housz-Oro, S, Blanchet-Bardon, C, Vrillat, M, Dubertret, L

“…ABSTRACT Background  In recessive dystrophic epidermolysis bullosa (RDEB), a good nutritional balance is necessary to obtain healing of the chronic wounds…”
Get full text

Atorvastatin-induced drug reaction with eosinophilia and systemic symptoms (DRESS) by Gressier, L, Pruvost-Balland, C, Dubertret, L, Viguier, M

“…Atorvastatin is a widely-used therapeutic statin given for hypercholesterolaemia and for prevention of cardiovascular events. We report herein the occurrence…”
Get full text

Review of the potential photo-cocarcinogenicity of topical calcineurin inhibitors: position statement of the European Dermatology Forum by Ring, J, Barker, J, Behrendt, H, Braathen, L, Darsow, U, Dubertret, L, Giannetti, A, Hawk, J, Hönigsmann, H, Kemeny, L, Luger, T, Meurer, M, Murphy, G, Peserico, A, Ranki, A, Reunala, T, Saurat, J, Sterry, W, van de Kerkhof, P

“…Topical Calcineurin Inhibitors (TCIs) used for the treatment of atopic eczema modify the immune regulatory function of the skin and may have the potential to…”
Get full text